The group is participating in the DIRECT SAFE trial - A randomized controlled trial of DIRECT endovascular clot retrieval versus standard bridging thrombolysis with endovascular clot retrieval within 4.5 hours of stroke onset. Anne Hege Aamodt is PI at Oslo University Hospital for this large multi-center thrombectomy trial that is lead from Melbourne.

The group is participating in the ELAN trial: Early versus late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN: an international, multicentre, randomised-controlled, two-arm, assessor-blinded trial.

AI-STROKE is a collaboration project with radiological departments and stroke units in the South-Eastern Norway Regional Health Authority, the University of Calgary and the University Hospital of North Norway with main aim of the project is to organise and simplify the care pathway through a pragmatic approach to acute stroke imaging powered by cutting edge advances in image processing and artificial intelligence. By utilizing the strong collaboration between stroke units and radiological departments we are using AI-based image analysis tools applied to already available standard CT based imaging techniques to improve acute stroke diagnostics and increase the number of patients treated by EVT.

Multi-disciplinary Translational Project for Improving Patient Care in Norway and Unraveling the Mysteries of Moyamoya Disease” – a multi-disciplinary prospective observational study that is lead together with the Department of Neurosurgery in in collaboration with the Department of Nuclear Medicine and Radiology. The aim is to establish a structured «one-door-in» strategy with a streamlined and state of the art diagnostic work-up and a dedicated multi-disciplinary team approach for treatment and follow-up to improve the care, safety, and outcome for moyamoya angiopathy patients in Norway. The projects is funded by Stiftelsen Dam and Odd Fellow. In collaboration with the Department of Medicial Genetics we are also running a project of etiology and patho-mechanisms in moyamoya disease.

All-In: HUNTing for genes affecting cerebrovascular diseases

The group is participating in the all-in HUNT 4 – The Nord-Trøndelag Health Study. 

The group is participating in a project to the burden of brain diseases in Norway based on data from GBD 2016.

The Institute for Health Metrics and Evaluation (IHME) at the University of Washington is leading the Global Burden of Disease project. Everyone, all over the world, deserves to live a long life in full health. In order to achieve this goal, we need a comprehensive picture of what disables and kills people across countries, time, age, and sex. The Global Burden of Disease (GBD) provides a tool to quantify health loss from hundreds of diseases, injuries, and risk factors, so that health systems can be improved and disparities can be eliminated. In order to align health systems with the populations they serve, policymakers first need to understand the true nature of their country’s health challenges – and how those challenges are shifting over time. That means more than just estimating disease prevalence, such as the number of people with depression or diabetes in a population. GBD research incorporates both the prevalence of a given disease or risk factor and the relative harm it causes. The tools allow decision-makers to compare the effects of different diseases, such as malaria versus cancer, and then use that information at home. To make these results more accessible and useful, IHME has distilled large amounts of complicated information into a suite of interactive data visualizations that allow people to make sense of the over 1 billion data points generated. Collected and analyzed by a consortium of more than 2,300 researchers in more than 130 countries, the data capture premature death and disability from more than 300 diseases and injuries in 195 countries, by age and sex, from 1990 to the present, allowing comparisons over time, across age groups, and among populations. The flexible design of the GBD machinery allows for regular updates as new data and epidemiological studies are made available. In that way, the tools can be used at the global, national, and local levels to understand health trends over time, just like gross domestic product data are used to monitor a country’s economic activity.

Policymakers in countries worldwide are collaborating with GBD researchers to adopt this approach for measuring their population’s health and how it varies by different regions, socioeconomic status, or ethnic groups in their country.

Homepage: www.ecri.no

ECRI is developed to facilitate large multi-center clinical cerebrovascular studies. The Norwegian Tenecteplase in stroke Trial (NOR-TEST) was the first multi-center study in ECRI to be completed in ECRI (http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30253-3/fulltext).

A prospective observational study of intravenous thrombolysis in nonartertitic Central Retinal Artery Occlusion and Thrombolysis Study.

SITS AF 1 Study

A retrospective and prospective study to identify the safest and most effective time point for initiation of oral anticoagulation (OAC) following ischaemic stroke of different severity in patients with atrial fibrillation.

SITS AF 2 Study

A retrospective and prospective study is to investigate the type, timing, safety and reasons for choice of acute interventions in patients taking direct OACs or warfarin prior to stroke onset.